Conflicting results have been reported for the prognostic significance of IDH mutations.48–50 The initial target population for clinical trials of IDH inhibitors is unresectable and/or metastatic disease, and prognostic significance may vary based on the precise clinical setting. This evidence concerns the gene IDH2 and metastatic neoplasm.